Etoposide-13C,d3(Synonyms: VP-16-13C,d3; VP-16-213-13C,d3)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Etoposide-13C,d3 (Synonyms: VP-16-13C,d3; VP-16-213-13C,d3)

Etoposide-13C,d3 是一种 13C- 和氘代标记的 Etoposide。Etoposide (VP-16; VP-16-213) 是一种常用的抗肿瘤化疗剂。Etoposide 抑制拓扑异构酶 II (topoisomerase-II),从而抑制 DNA 复制。Etoposide 诱导细胞周期停滞,凋亡 (apoptosis) 和自噬 (autophagy)。

Etoposide-13C,d3(Synonyms: VP-16-13C,d3;  VP-16-213-13C,d3)

Etoposide-13C,d3 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Etoposide-13C,d3 is the 13C- and deuterium labeled. Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[65].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

592.57

Formula

C2813CH29D3O13

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.

    [2]. Lee KI, et al. Etoposide induces pancreatic β-cells cytotoxicity via the JNK/ERK/GSK-3 signaling-mediated mitochondria-dependent apoptosis pathway. Toxicol In Vitro. 2016 Jul 26. pii: S0887-2333(16)30147-3.

    [3]. Calvani M, det al. Etoposide-Anti-Human VEGF a new strategy against human melanoma cells expressing stem-like traits. Oncotarget. 2016 Jun 9. doi: 10.18632/oncotarget.9939.

    [4]. Fuchs, J., et al. Comparative activity of NSC 119875, NSC 109724, NSC 123127, NSC 241240, and etoposide in heterotransplanted hepatoblastoma. Cancer, 1998. 83(11): p. 2400-7.

    [5]. Hande KR, et al. The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example. Oncologist. 1996;1(4):234-239.

    [6]. Cui D, et al. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.Cell Rep. 2020 Jan 14;30(2):497-509.e4.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Etoposide(Synonyms: 依托泊苷; VP-16; VP-16-213)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Etoposide (Synonyms: 依托泊苷; VP-16; VP-16-213) 纯度: 99.86%

Etoposide (VP-16; VP-16-213) 是一种常用的抗肿瘤化疗剂。Etoposide 抑制拓扑异构酶 II (topoisomerase-II),从而抑制 DNA 复制。Etoposide 诱导细胞周期停滞,凋亡 (apoptosis) 和自噬 (autophagy)。

Etoposide(Synonyms: 依托泊苷; VP-16;  VP-16-213)

Etoposide Chemical Structure

CAS No. : 33419-42-0

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥567 In-stock
100 mg ¥515 In-stock
200 mg ¥880 In-stock
500 mg ¥2000 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Etoposide 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Apoptosis Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Natural Product Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Glycoside Compound Library
  • Antibacterial Compound Library
  • NMPA-Approved Drug Library
  • Phenols Library
  • Orally Active Compound Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library
  • Antibiotics Library
  • Anti-Lung Cancer Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Anti-Blood Cancer Compound Library
  • Mitochondria-Targeted Compound Library
  • Tumorigenesis Related Compound Library
  • Rare Diseases Drug Library
  • Children’s Drug Library

生物活性

Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1].

IC50 & Target[1]

Topoisomerase II

 

体外研究
(In Vitro)

Etoposide is capable of causing cytotoxicity on pancreatic β-cells by inducing apoptosis through the JNK/ERK-mediated GSK-3 downstream-triggered mitochondria-dependent signaling pathway in RIN-m5F cells[1].
Etoposide and Anti-Human VEGF significantly abolish P1 sphere-forming ability, an effect associated with apoptosis of this subset of cells[2].
Etoposide phosphate (0-1μM; 72 hours) inhibits HCT116 FBXW+/+, FBXW-/- and p53-/- as a dose-dependent manner, exhibits IC50s of 0.945 μM; 0.375 μM; and 1.437 μM, respectively[5].
Etoposide (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7-/- cells[5].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[5]

Cell Line: HCT116 FBXW+/+, FBXW-/- and p53-/- cells
Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
Incubation Time: 72 hours
Result: Inhibits HCT116 FBXW+/+p>, FBXW-/- and p53-/- cell growth as a concentration manner.

Western Blot Analysis[5]

Cell Line: HCT116 FBXW7+/+ or FBXW7-/- cells
Concentration: 25 μM
Incubation Time: 6 hours
Result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.

体内研究
(In Vivo)

Etoposide (50 μM) and Anti-Human VEGF-treated hypoxic cells injected intravenously into immunodeficient mice reveals a reduced capacity to induce lung colonies, which also appear with a longer latency period[2]. Etoposide (10 mg/kg/day, i.v.) with NSC 109724 and NSC 241240, reduces the tumor volume in the hepatoblastoma cell injected NMRI nude mice[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

588.56

Formula

C29H32O13

CAS 号

33419-42-0

中文名称

依托泊苷;臼乙叉苷;足叶乙甙

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

DMSO : ≥ 39 mg/mL (66.26 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6991 mL 8.4953 mL 16.9906 mL
5 mM 0.3398 mL 1.6991 mL 3.3981 mL
10 mM 0.1699 mL 0.8495 mL 1.6991 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.25 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.25 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

  • 3.

    请依序添加每种溶剂: 5% DMSO    40% PEG300    5% Tween-80    50% saline

    Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

  • 4.

    请依序添加每种溶剂: 5% DMSO    95% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

  • 5.

    请依序添加每种溶剂: 1% DMSO    99% saline

    Solubility: ≥ 0.5 mg/mL (0.85 mM); Clear solution

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Lee KI, et al. Etoposide induces pancreatic β-cells cytotoxicity via the JNK/ERK/GSK-3 signaling-mediated mitochondria-dependent apoptosis pathway. Toxicol In Vitro. 2016 Jul 26. pii: S0887-2333(16)30147-3.

    [2]. Calvani M, det al. Etoposide-Anti-Human VEGF a new strategy against human melanoma cells expressing stem-like traits. Oncotarget. 2016 Jun 9. doi: 10.18632/oncotarget.9939.

    [3]. Fuchs, J., et al. Comparative activity of NSC 119875, NSC 109724, NSC 123127, NSC 241240, and etoposide in heterotransplanted hepatoblastoma. Cancer, 1998. 83(11): p. 2400-7.

    [4]. Hande KR, et al. The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example. Oncologist. 1996;1(4):234-239.

    [5]. Cui D, et al. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.Cell Rep. 2020 Jan 14;30(2):497-509.e4.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Etoposide phosphate(Synonyms: 磷酸依托泊苷; BMY-40481)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Etoposide phosphate (Synonyms: 磷酸依托泊苷; BMY-40481) 纯度: 98.40%

Etoposide phosphate (BMY-40481) 是一种有效的抗癌 (anti-cancer) 化疗试剂和一种选择性拓扑异构酶 II (topoisomerase II) 抑制剂,可以防止 DNA 链的重新连接。Etoposide phosphate 是依托泊苷的磷酸酯前药,被认为与 Etoposide 活性相当。Etoposide phosphate 诱导细胞周期阻滞、凋亡 (apoptosis) 和自噬 (autophagy)。

Etoposide phosphate(Synonyms: 磷酸依托泊苷; BMY-40481)

Etoposide phosphate Chemical Structure

CAS No. : 117091-64-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in Water ¥1177 In-stock
5 mg ¥800 In-stock
10 mg ¥1300 In-stock
25 mg ¥2600 In-stock
50 mg ¥4100 In-stock
100 mg ¥6500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Etoposide phosphate 相关产品

相关化合物库:

  • Natural Product Like Compound Library
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Apoptosis Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Antibacterial Compound Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Anti-Lung Cancer Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Anti-Blood Cancer Compound Library
  • Tumorigenesis Related Compound Library
  • Rare Diseases Drug Library
  • Children’s Drug Library

生物活性

Etoposide phosphate (BMY-40481) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate is the phosphate ester prodrug of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate induces cell cycle arrest, apoptosis, and autophagy[1][2].

IC50 & Target[1]

Topoisomerase II

 

体外研究
(In Vitro)

Etoposide phosphate is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4′ of the E ring of the etoposide molecule[1].
Etoposide phosphate (0-1 μM; 72 hours) inhibits HCT116 FBXW+/+, FBXW-/- and p53-/- as a dose-dependent manner, exhibits IC50 values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively[2].
Etoposide phosphate (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7-/- cells[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: FBXW+/+, FBXW-/- and p53-/- cell
Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
Incubation Time: 72 hours
Result: Inhibited HCT116 FBXW+/+, FBXW-/- and p53-/- cell growth as a concentration manner.

Western Blot Analysis[2]

Cell Line: HCT116 FBXW7+/+ or FBXW7-/- cells
Concentration: 25 μM
Incubation Time: 6 hours
Result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.

体内研究
(In Vivo)

Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8 in female CD-1 mice[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CD-1 mice[3]
Dosage: 50, 100, or 150 mg/kg
Administration: Intravenous injection; single dose
Result: Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral nerves, dorsal spinal roots, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM).

Clinical Trial

分子量

668.54

Formula

C29H33O16P

CAS 号

117091-64-2

中文名称

磷酸依托泊苷

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

H2O : 125 mg/mL (186.97 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.4958 mL 7.4790 mL 14.9580 mL
5 mM 0.2992 mL 1.4958 mL 2.9916 mL
10 mM 0.1496 mL 0.7479 mL 1.4958 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Witterland AH, et al. Etoposide phosphate, the water soluble prodrug of etoposide. Pharm World Sci. 1996 Oct;18(5):163-70.

    [2]. Cui D, et al. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.Cell Rep. 2020 Jan 14;30(2):497-509.e4.

    [3]. Bregman CL, et al. Etoposide- and BMY-40481-induced sensory neuropathy in mice.Toxicol Pathol. 1994 Sep-Oct;22(5):528-35.

    [4]. SUMMARY OF PRODUCT CHARACTERISTICS

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Etoposide phosphate disodium(Synonyms: BMY-40481 disodium)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Etoposide phosphate disodium (Synonyms: BMY-40481 disodium)

Etoposide phosphate disodium (BMY-40481 disodium) 是一种有效的抗癌 (anti-cancer) 化疗试剂和一种选择性拓扑异构酶 II (topoisomerase II) 抑制剂,可以防止 DNA 链的重新连接。Etoposide phosphate disodium 是依托泊苷的磷酸酯前药,被认为与 Etoposide 活性相当。Etoposide phosphate disodium 诱导细胞周期阻滞、凋亡 (apoptosis) 和自噬 (autophagy)。

Etoposide phosphate disodium(Synonyms: BMY-40481 disodium)

Etoposide phosphate disodium Chemical Structure

CAS No. : 122405-33-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Etoposide phosphate disodium 的其他形式现货产品:

Etoposide phosphate

生物活性

Etoposide phosphate disodium (BMY-40481 disodium) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate disodium is the phosphate ester prodrug of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate disodium induces cell cycle arrest, apoptosis, and autophagy[1][2].

IC50 & Target[2]

Topoisomerase II

 

体外研究
(In Vitro)

Etoposide phosphate disodium is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4′ of the E ring of the etoposide molecule[1].
Etoposide phosphate disodium (0-1 μM; 72 hours) inhibits HCT116 FBXW+/+, FBXW-/- and p53-/- as a dose-dependent manner, exhibits IC50 values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively[2].
Etoposide phosphate disodium (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7-/- cells[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: FBXW+/+, FBXW-/- and p53-/- cell
Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
Incubation Time: 72 hours
Result: Inhibited HCT116 FBXW+/+, FBXW-/- and p53-/- cell growth as a concentration manner.

Western Blot Analysis[2]

Cell Line: HCT116 FBXW7+/+ or FBXW7-/- cells
Concentration: 25 μM
Incubation Time: 6 hours
Result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.

体内研究
(In Vivo)

Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8 in female CD-1 mice[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CD-1 mice[3]
Dosage: 50, 100, or 150 mg/kg
Administration: Intravenous injection; single dose
Result: Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral nerves, dorsal spinal roots, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM).

Clinical Trial

分子量

712.50

Formula

C29H31Na2O16P

CAS 号

122405-33-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Witterland AH, et al. Etoposide phosphate, the water soluble prodrug of etoposide. Pharm World Sci. 1996 Oct;18(5):163-70.

    [2]. Cui D, et al. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.Cell Rep. 2020 Jan 14;30(2):497-509.e4.

    [3]. Bregman CL, et al. Etoposide- and BMY-40481-induced sensory neuropathy in mice.Toxicol Pathol. 1994 Sep-Oct;22(5):528-35.

    [4]. SUMMARY OF PRODUCT CHARACTERISTICS

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务